gpt-dict.com

Chromium for Insulin Resistance

Verdict: Weak, surrogate-only evidence; not a reliable fix

Chromium supplements have not been shown to reliably improve insulin resistance. The few positive signals come only from a lab marker (HOMA-IR), are highly inconsistent, and major health authorities consider any benefit unproven.

C 🟠 C Weak Evidence Published

🔬Why this grade7-layer evidence engine

The grade is Weak Evidence because every favorable finding rests on a surrogate blood marker rather than real-world outcomes like diabetes prevention. A 2020 meta-analysis of 28 trials (PMID 32730903) reported a statistically significant drop in HOMA-IR, but its heterogeneity was extreme (I-squared 89.9%), which badly undercuts confidence in that pooled estimate.

The trial evidence also openly contradicts itself. A 2015 meta-analysis (PMID 25971249, 875 patients) found no effect of chromium picolinate or yeast on HbA1c, and only a brewer's-yeast subgroup lowered fasting glucose. Suksomboon 2014 (PMID 24635480) saw better glycemic control overall but called the insulin-resistance signal weak and inconsistent. In PCOS, Tang 2018 (PMID 28929602) and Hamsho 2025 (PMID 41067797) improved HOMA-IR yet showed no change in fasting insulin, with testosterone paradoxically rising.

Regulators and clinics reinforce the caution. The US FDA calls the chromium-insulin resistance link 'highly uncertain,' the EU's EFSA found no proven benefit and judges chromium non-essential, the UK NHS endorses no health claims, and the NIH Office of Dietary Supplements notes any effect has 'little clinical significance.' Lifestyle change and, where appropriate, metformin remain the proven first-line approaches.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.50
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published
Confidence
62%
Broadly consistent
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive
L2 PubMedPrimary literature
0.45
L3 MechanismPlausibility
0.45
L1 ExamineGlobal benchmark
0.50
L11 AI re-checkIndependent read
0.50
L5 Clinical bodiesAuthoritative stance
0.59
Against Mixed Supports
▸View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.496
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (3 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標，未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (5)L2 · primary research & systematic reviews

Systematic review and meta-analysis of the efficacy and safety of chromium supplementation in diabetes
PMID: 24635480 2014 統合分析
Finding: Chromium mono- and combined supplementation significantly improved glycemic control (HbA1c, FPG); evidence for fasting insulin and HOMA-IR less consistent; safety acceptable at studied doses.
Academic Effect size: [object Object]
View on PubMed
Effect of chromium supplementation on glycated hemoglobin and fasting plasma glucose in patients with diabetes mellitus
PMID: 25971249 2015 統合分析 n = 875
Finding: Cr yeast, brewer's yeast and Cr picolinate showed no statistically significant effects on HbA1c. Only brewer's yeast showed significant FPG reduction; other chromium forms showed no FPG effect. HOMA-IR was not reported as a primary endpoint.
Academic Effect size: [object Object]
View on PubMed
Effects of chromium supplementation on glycemic control in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
PMID: 32730903 2020 統合分析
Finding: Pooled analysis showed significant HOMA-IR reduction with chromium supplementation (WMD -1.53, 95% CI -2.35 to -0.72, p<0.001) in T2DM, but with very high heterogeneity (I2=89.9%). Effects on FPG, insulin and HbA1c also reached significance with similarly high heterogeneity.
🟠 Limited quality Academic Effect size: [object Object]
View on PubMed
Chromium supplementation in women with polycystic ovary syndrome: Systematic review and meta-analysis
PMID: 28929602 2018 統合分析 n = 351
Finding: HOMA-IR significantly decreased (SMD -0.84, 95% CI -1.30 to -0.38, p=0.0004); however, fasting insulin, FBS, BMI and QUICKI showed no significant change. Total/free testosterone paradoxically increased. Authors conclude chromium 'may not have significant benefits' for PCOS overall.
Academic Effect size: [object Object]
View on PubMed
Therapeutic effects of chromium supplementation on women with polycystic ovarian syndrome: A systematic review and meta-analysis
PMID: 41067797 2025 統合分析 n = 683
Finding: Chromium picolinate reported as more effective than metformin in reducing HOMA-IR (p<0.00001); improvements in fasting insulin and lipid profile reported, but specific MD/CI for HOMA-IR not provided in abstract. Authors stress need for more trials before dietary guidelines.
🟠 Limited quality Academic Effect size: [object Object]
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
One small study suggests that chromium picolinate may reduce the risk of insulin resistance, and therefore possibly may reduce the risk of type 2 diabetes. FDA concludes, however, that the existence of such a relationship between chromium picolinate and either insulin resistance or type 2 diabetes is highly uncertain. source↗
L4b EU EFSA
Against
The Panel concludes that there is no evidence of beneficial effects associated with chromium intake in healthy subjects ... no Average Requirement (AR) and Population Reference Intake (PRI) can be defined; chromium is not an essential nutrient. source↗
L4c UK NHS
Cautious
You should be able to get all the chromium you need by eating a varied and balanced diet. Around 25 micrograms of chromium a day should be enough for adults. Having 10mg or less a day of chromium from food and supplements is unlikely to cause any harm. source↗
L4d TW TFDA / 衛福部
Supportive
每日食用量中，其鉻之總含量不得高於200微克 source↗
L4e WHO
Not addressed
Chromium[VI] is carcinogenic to humans (Group 1). Metallic chromium and chromium[III] compounds are not classifiable as to their carcinogenicity to humans (Group 3). source↗
L5a NIH Office of Dietary Supplements
Cautious
Research suggests that chromium supplementation reduces body weight and body fat percentage to a very small, but statistically significant, extent. However, these effects have little clinical significance. source↗
L5b Mayo Clinic
Cautious
L5d Harvard Health
Cautious
L5e Specialty Society (condition-mapped)
Supportive
✓PMID 100% verifiedevery citation checked via NCBI Entrez
🔬5 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-insulin-resistance-INT-chromium-001 繁體中文版 →